Commencement of Development Program. As soon as Vertex has identified a Development Candidate which it believes meets the Development Candidate Criteria, it will so notify CFFT and the JRC and will include with that notice the Development Candidate Information with respect to that Development Candidate and its Back-up Compounds. Vertex will promptly commence and pursue a Development Program with respect to that Development Candidate, at its expense, applying diligent, commercially reasonable efforts to develop Drug Product Candidates into Drug Products, consistent with those used by Vertex for its own compounds of similar potential.
Commencement of Development Program. As soon as Vertex has identified a Development Candidate which it believes meets the Development Candidate Criteria, it will so notify CFFT and the JRC and will include Information redacted pursuant to a confidential treatment request. An unredacted version of this exhibit has been separately filed with the Commission. with that notice the Development Candidate Information with respect to that Development Candidate and its Back-up Compounds. Vertex will promptly commence and pursue a Development Program with respect to that Development Candidate, at its expense, applying diligent, commercially reasonable efforts to develop Drug Product Candidates into Drug Products, consistent with those used by Vertex for its own compounds of similar potential.
Commencement of Development Program. NOVARTIS shall promptly and diligently commence and pursue a Development Program with respect to each Drug Product Candidate as soon as practicable after exercise by NOVARTIS of its Development Election with respect to that Drug Product Candidate.
Commencement of Development Program. GSK shall use Commercially Reasonable Efforts to pursue a Development Program with respect to the Product Candidates in accordance with the provisions of this Agreement. The Development Program shall proceed in accordance with a Development Plan that provides for development of one or more Product Candidates or Products in the Territory. An initial summary Development Plan, currently focused on VX-409, is attached to this Agreement as Schedule 3.1. A completed Development Plan, as described in Section 3.4.1, shall be prepared by GSK and reviewed by the JSC, within [***] after the Effective Date (or such longer period as mutually agreed), and shall be modified and updated by GSK on a regular basis, with input from the JSC and the JDT as provided below.
Commencement of Development Program. Promptly after the Effective Date, Avalon shall commence and diligently pursue the Development Program (as more particularly set forth in Section 3.6 of this Agreement) with respect to the Compound in accordance with the Development Plan.
Commencement of Development Program. SCHERING and VERTEX shall promptly and diligently commence and pursue a Development Program with respect to each Program Compound as soon as practicable after exercise by SCHERING of its Development Option, as set forth in the Research Agreement, with respect to that Program Compound.
Commencement of Development Program. SERONO and VERTEX shall promptly and diligently commence and pursue a Development Program with respect to the Drug Product Candidate as soon as practicable after exercise by SERONO of its Development Election, as set forth in the Research Agreement, with respect to that Drug Product Candidate.
Commencement of Development Program. 12 3.2 International Project Team............................................................................13 3.3
Commencement of Development Program. NOVARTIS shall promptly and diligently commence and pursue a Development Program with respect to each Drug Candidate as soon as practicable after exercise by NOVARTIS of its Development Election with respect to that Drug Candidate. Any Drug Candidate for which a Development Program has been commenced by NOVARTIS hereunder shall be called a Drug Product Candidate under this Agreement. The provisions set forth in this Article III shall not apply to any Subsequent Candidates or Drug Candidates accepted by NOVARTIS at the Second Opportunity as to which development and marketing will proceed in the form of a joint venture, as provided in Section 7.4.2.
Commencement of Development Program. Promptly after the Effective Date, Avalon shall commence and diligently pursue the Development Program (as more particularly set forth in Section 3.6 of this Agreement) with respect to the Compound in accordance with the Development Plan. * The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted separately to the Securities and Exchange Commission.
